| Literature DB >> 30210314 |
Levente Szalardy1, Mate F Molnar1, Denes Zadori1, Edina K Cseh1, Gabor Veres1,2, Gabor G Kovacs3, Laszlo Vecsei1,2, Peter Klivenyi1.
Abstract
Dysfunction of peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1α) has been linked to various neurodegenerative and neuropsychiatric disorders; however, reports on psychic behavioral alterations on PGC-1α-deficient animals are sparse. The present study revisited prior observations of anxiety-related, depression-related, and hippocampal memory-related observations having been made on different PGC-1α-deficient murine strains, in a large-scale analysis on whole-body full-length (FL-)PGC-1α-deficient mice. The examinations were performed on animals covering a wide age range enrolled from both sexes, and included paradigms such as the open-field, elevated plus maze, light-dark box, tail suspension test, and spatial recognition two-trial Y-maze. The findings revealed no signs of previously reported anxiety-like behavior, but revealed an unexpected phenotype with decreased anxiety behavior consistent throughout different paradigms, with slight male preponderance. This was associated with despair-like anhedonic behavior, consistent with that reported previously, but did not associate with either peripheral or brain alterations in kynurenic acid synthesis, which was previously proposed. Though male FL-PGC-1α-deficient mice tended to perform poorer in the hippocampus-based spatial learning paradigm, the genotype overall was not associated with impairment in spatial memory, contradicting with prior observations. None of the observed alterations deteriorated with age, similarly to motor alterations as reported previously. The most likely contributors of this peculiar phenotype are discussed, with clinicopathological correlations drawn. Being the first to address these behavioral domains within the same PGC-1α-deficient strain, our findings extend the knowledge about the complex in vivo effect of PGC-1α dysfunction and add important notes to research in the field of PGC-1α in connection with neuropsychiatric disorders.Entities:
Keywords: PGC-1α; anxiety; behavior; depression; memory; peroxisome proliferator-activated receptor gamma coactivator
Year: 2018 PMID: 30210314 PMCID: PMC6119962 DOI: 10.3389/fnbeh.2018.00180
Source DB: PubMed Journal: Front Behav Neurosci ISSN: 1662-5153 Impact factor: 3.558
Description of experimental cohorts used to asses different behavioral domains.
| FL-PGC-1α -/- | Wild-type | |||
|---|---|---|---|---|
| 26 | 34 | – | ||
| Female/male | 14/12 | 17/17 | 0.768 | |
| Age | w | 39.8 [17.9–51.1] | 39.7 [21.9–62.5] | 0.627 |
| Younger/older | 13/13 | 17/17 | ||
| 37 | 42 | – | ||
| Female/male | 18/19 | 20/22 | 0.927 | |
| Age | w | 54.9 [27.6–71.9] | 56.0 [45.6–71.6] | 0.420 |
| Younger/older | 17/20 | 19/23 | ||
| 30 | 30 | – | ||
| Female/male | 15/15 | 15/15 | 1.000 | |
| Age | w | 45.9 [20.1–51.9] | 42.0 [41.9–64.1] | 0.477 |
| Younger/older | 14/16 | 15/15 | ||
Assessment of between-sex differences in the semi-quantitative scores of brain vacuolation in FL-PGC-1α-deficient mice in selected brain regions.
| Vacuolation | Male | Female | |
|---|---|---|---|
| Anterior Commissure | 2.9 ± 0.3 | 2.1 ± 0.1 | 0.152 |
| Hippocampusmed | 1.0 ± 0.3 | 1.3 ± 0.3 | 1.000 |
| Hippocampuslat | 1.9 ± 0.5 | 2.0 ± 0.0 | 1.000 |
| Thalamusmed | 2.5 ± 0.3 | 1.6 ± 0.2 | 0.236 |
| Thalamuslat | 3.5 ± 0.3 | 3.6 ± 0.2 | 1.000 |
| Nucleus accumbens | 3.0 ± 0.4 | 2.1 ± 0.3 | 0.190 |
| Mammillary body | 1.7 ± 0.5 | 2.6 ± 0.3 | 0.592 |
| Mesencephalonmed | 2.4 ± 0.2 | 2.6 ± 0.3 | 1.000 |
| Mesencephalonlat | 3.0 ± 0.0 | 2.5 ± 0.5 | 0.333 |
| Pontomedullary brainstemmed | 3.3 ± 0.2 | 2.6 ± 0.2 | 0.058 |
| Pontomedullary brainstemlat | 2.1 ± 0.1 | 1.7 ± 0.5 | 0.054 |
| Cerebellar cortexmed | 0.3 ± 0.2 | 1.1 ± 0.2 | 0.125 |
| Cerebellar cortexlat | 0.3 ± 0.2 | 0.3 ± 0.2 | 1.000 |
| Cerebellar nucleimed | 2.3 ± 0.3 | 2.0 ± 0.0 | 1.000 |
| Cerebellar nucleilat | 2.3 ± 0.3 | 2.0 ± 0.4 | 1.000 |
| Cerebellar white mattermed | 1.8 ± 0.3 | 2.0 ± 0.2 | 0.765 |
| Cerebellar white matterlat | 2.0 ± 0.2 | 1.6 ± 0.4 | 0.648 |
| Fasciculus retroflexus | 4.0 ± 0.0 | 4.0 ± 0.0 | 1.000 |
| Motor cortex | 2.0 ± 0.0 | 1.4 ± 0.5 | 0.054 |
| Sensory cortex | 2.9 ± 0.1 | 2.3 ± 0.2 | 0.103 |
| Visual cortex | 2.6 ± 0.2 | 2.6 ± 0.2 | 1.000 |
| Insular cortex | 2.2 ± 0.2 | 1.8 ± 0.2 | 1.000 |
| Striatum | 4.0 ± 0.0 | 4.0 ± 0.0 | 1.000 |
| Globus pallidus | 2.7 ± 0.3 | 2.7 ± 0.3 | 1.000 |
| Amygdala | 1.4 ± 0.7 | 0.8 ± 0.3 | 0.420 |
| Stria terminalis | 2.7 ± 0.3 | 2.9 ± 0.3 | 1.000 |
| Internal capsule | 3.5 ± 0.2 | 3.7 ± 0.2 | 0.592 |
| Fimbria hippocampi | 1.8 ± 0.3 | 0.9 ± 0.3 | 0.273 |
| Optic tract | 0.3 ± 0.2 | 0.5 ± 0.3 | 1.000 |
| Olfactory tract | 2.0 ± 0.4 | 2.1 ± 0.3 | 0.767 |
Assessment of the effect of FL-PGC-1α-deficiency on kynurenic acid synthesis in the murine liver and brain (HPLC).
| FL-PGC-1α -/- | Wild-type | |||
|---|---|---|---|---|
| 15 | 16 | – | ||
| Female/male | 7/8 | 8/8 | 0.853 | |
| KYNA | pmol/g ww | 154.4 [0.0–173.6] | 144.6 [122.2–271.8] | 0.495 |
| TRP | nmol/g ww | 193.2 [61.6–418.2] | 170.6 [117.9–398.6] | 0.470 |
| KYNA/TRP | % | 0.09 [0.00–0.23] | 0.09 [0.02–0.22] | 0.892 |
| 6 | 8 | – | ||
| Female/male | 0/6 | 0/8 | 1.000 | |
| KYNA striatum | pmol/g ww | 41.9 [0.0–157.5] | 0.0 [0.0–143.8] | 0.662 |
| TRP striatum | nmol/g ww | 31.8 ± 6.2 | 22.7 ± 1.5 | 0.205 |
| KYNA/TRP striatum | % | 0.10 [0.00–0.77] | 0.00 [0.00–0.61] | 0.852 |
| KYNA cerebellum | pmol/g ww | 18.0 ± 9.1 | 27.7 ± 8.2 | 0.448 |
| TRP cerebellum | nmol/g ww | 42.2 ± 6.2 | 41.2 ± 6.1 | 0.908 |
| KYNA/TRP cerebellum | % | 0.02 [0.00–0.12] | 0.06 [0.02–0.22] | 0.573 |
Previous reports on non-motor behavioral alterations of PGC-1α-deficient and transgenic animals.
| Publication | Strain | Behavior | Paradigm(s) | Findings | Age | Sex | Subject number |
|---|---|---|---|---|---|---|---|
| Whole-body FL-PGC-1α | Anxiety | Open-field | Thigmotaxis | 3.5 m | Male | ||
| Muscle-specific PGC-1α transgenic | Despair | Forced-swim test | Decreased immobility after CMS, no baseline difference | 12–13 w | Male | ||
| Sucrose consumption | Increased after CMS, no baseline difference | ||||||
| Muscle-specific PGC-1α | Sucrose consumption | Decreased (anhedonia) | N/A | N/A | |||
| PV+ neuron-specific PGC-1α | Hippocampal memory | Barnes maze test | Increased distance traveled to reach the escape box | 3 (or 6) m | Male | ||
| Whole-body PGC-1α | Hippocampal function | Nest building | Impaired | 2 m | Mixed | ||
| PV+ neuron-specific PGC-1α | Impaired | 2–8 m | N/A | ||||